Study Number: C11297-01

Test Type: TOX Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

C Number:

Study Gender:

PWG Approval Date

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

CAS Number: 25637-99-4

Lab: Battelle

Date Report Requested: 04/26/2019

Time Report Requested: 07:40:14

C11297-01

Male

See web page for date of PWG Approval

Study Number: C11297-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

CAS Number: 25637-99-4

Date Report Requested: 04/26/2019 Time Report Requested: 07:40:14

Lab: Battelle

Male: Core Males

	Treatment Groups (mg/kg)							
	0	0.06	0.641	6.41	64.1	641		
Disposition Summary Animals Initially In Study Scheduled Sacrifice Early Deaths	6	6	6	6	6	6		
Survivors Scheduled sacrifice, terminal (SD 5) Animals Examined Microscopically	6 6	6	6	6	6 5	6 6		
ALIMENTARY SYSTEM LIVER	(6)	(0)	(0)	(0)	(5)	(6)		
CARDIOVASCULAR SYSTEM No Tissues/Organs Examined								
ENDOCRINE SYSTEM THYROID GLAND	(6)	(0)	(0)	(0)	(0)	(6)		
GENERAL BODY SYSTEM No Tissues/Organs Examined								
GENITAL SYSTEM No Tissues/Organs Examined								
HEMATOLYMPHOID SYSTEM No Tissues/Organs Examined								
INTEGUMENTARY SYSTEM No Tissues/Organs Examined								
MUSCULOSKELETAL SYSTEM No Tissues/Organs Examined								
NERVOUS SYSTEM No Tissues/Organs Examined								

Study Number: C11297-01

Test Type: TOX

Route: Oral Gavage

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

CAS Number: 25637-99-4

Date Report Requested: 04/26/2019 Time Report Requested: 07:40:14

Lab: Battelle

Species/Strain: Rat/Sprague Dawley

Male: Core Males								
	Treatment Groups (mg/kg)							
	0	0.06	0.641	6.41	64.1	641		
RESPIRATORY SYSTEM No Tissues/Organs Examined								
SPECIAL SENSES SYSTEM No Tissues/Organs Examined								
URINARY SYSTEM No Tissues/Organs Examined								
No Systemic Lesions								

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

CAS Number: 25637-99-4

Date Report Requested: 04/26/2019 Time Report Requested: 07:40:14

Lab: Battelle

Species/Strain: Rat/Sprague Dawley

Study Number: C11297-01

Test Type: TOX

Route: Oral Gavage

Tumor Summary Data for Male Core Males	Treatment Groups (mg/kg)						
	0	0.06	0.641	6.41	64.1	641	
Total Animals with Primary Neoplasms	0	0	0	0	0	0	
Total Primary Neoplasms	0	0	0	0	0	0	
Total Animals with Benign Neoplasms	0	0	0	0	0	0	
Total Benign Neoplasms	0	0	0	0	0	0	
Total Animals with Malignant Neoplasms	0	0	0	0	0	0	
Total Malignant Neoplasms	0	0	0	0	0	0	
Total Animals with Metastatic Neoplasms	0	0	0	0	0	0	
Total Metastatic Neoplasms	0	0	0	0	0	0	
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0	0	

Study Number: C11297-01 PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

Route: Oral Gavage CAS Number: 25637-99-4 Lab: Battelle

Species/Strain: Rat/Sprague Dawley

Test Type: TOX

Date Report Requested: 04/26/2019 Time Report Requested: 07:40:14

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

(a) Systemic lesions are included once in the total lesion count regardless of how many times they occurred in a single animal

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day

** END OF REPORT **